Bipartisan prescription drug price legislation hits snag - Bloomberg

A Senate committee markup of bills related to lower prescription drug prices is on hold as members on both sides of the aisle disagree over how the legislation should proceed.
Senate Committee on Health, Education, Labor and Pensions Chairman Bernie Sanders (I-Vt.) said Tuesday that the markup is in recess until May 11.
On May 10, the committee will hold a hearing with executives from pharmacy benefit managers and insulin manufacturers.
Sen. Bill Cassidy (R-La.), the committee's ranking member, was unhappy that several amendments up for discussion had been removed, Bloomberg reported.
In a statement, Sanders said "there was a difference of opinion on the process to include these amendments."
On May 10, executives from CVS Caremark (NYSE:CVS), Cigna Express Scripts, which is owned by Cigna Group (CI), and UnitedHealth Group Inc.'s (NYSE:UNH) OptumRx are scheduled to testify. Execs from Eli Lilly (NYSE:LLY), Novo Nordisk (NVO), and Sanofi (SNY) are also slated to appear.

More on drug pricing legislation